Telix Pharmaceuticals Limited (TLX)vsVertex Pharmaceuticals Inc (VRTX)
TLX
Telix Pharmaceuticals Limited
$8.90
+1.48%
HEALTHCARE · Cap: $3.28B
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 1707% more annual revenue ($12.00B vs $664.23M). VRTX leads profitability with a 32.9% profit margin vs 1.6%. VRTX trades at a lower P/E of 29.3x. VRTX earns a higher WallStSmart Score of 66/100 (B-).
TLX
Avoid32
out of 100
Grade: F
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-4850.0%
Fair Value
$0.14
Current Price
$8.90
$8.76 premium
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 58.9% year-over-year
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Distress zone — elevated risk
ROE of 3.1% — below average capital efficiency
1.6% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : TLX
The strongest argument for TLX centers on Revenue Growth. Revenue growth of 58.9% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : TLX
The primary concerns for TLX are EPS Growth, Altman Z-Score, Return on Equity. A P/E of 475.5x leaves little room for execution misses. Thin 1.6% margins leave little buffer for downturns.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
TLX profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
TLX carries more volatility with a beta of 1.22 — expect wider price swings.
TLX is growing revenue faster at 58.9% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 32/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Telix Pharmaceuticals Limited
HEALTHCARE · BIOTECHNOLOGY · USA
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company is headquartered in North Melbourne, Australia.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?